Fosinopril mediates antitumor efficacy by inducing GSDME-dependent pyroptosis in NSCLC.

ABSTRACT: Repurposing existing drugs offers a promising approach to cancer therapy. Fosinopril, an angiotensin converting enzyme inhibitor (ACEI) approved for hypertension, has demonstrated antitumor effects in hepatocellular carcinoma. However, its activity in non-small cell lung cancer (NSCLC) remains poorly understood. Here, we explore the potential anti-NSCLC effects of fosinopril in vitro and in vivo and its action mechanisms. The antiproliferative effects of fosinopril on NSCLC cells were assessed through the A549 and H1299 cell lines. Network pharmacology and proteomics were utilized to predict fosinopril's molecular mechanisms in NSCLC. A subcutaneous xenograft model in nude mice was established to evaluate the in vivo anticancer effects and mechanisms of fosinopril. Fosinopril significantly

SUBMITTER: Gao Y 

PROVIDER: S-EPMC12638797 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature